title: [Effect of mexidol (2-ethyl-6-methyl-3-oxypyridine succinate) on the quality of life and depressive symptoms in women with rheumatoid arthritis].
abstract: A prospective, randomized controlled study of the effects of 2-ethyl-6-methyl-3-oxypyridine succinate (mexidol) on the dynamics of articular syndrome, quality of life, and clinical manifestations of depression has been performed in a group of 62 women with rheumatoid arthritis diagnosis during therapy for two weeks. The use of mexidol in the complex treatment contributed to a decrease of the intensity of rheumatoid inflammation, reduction in the severity of depressive symptoms, and improvement of the functional status and quality of life.
authors: A V
authors: AV
authors: Sineglazova
authors: I A
authors: IA
authors: Volchegorskiĭ
mesh_terms: D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D003863:Depression / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D010847:Picolines / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D011619:Psychotropic Drugs / Q000494:pharmacology / Q000627:therapeutic use*; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D010847:Picolines; D011619:Psychotropic Drugs; C070020:emoxypine succinate